Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an orally active, direct-acting P2Y12 receptor antagonist. It is a member of the cyclopentyltriazolopyrimidine (CPTP) class and reversibly inhibits platelet aggregation.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of cardiovascular events, including cardiovascular death, myocardial infarction, and stroke, in patients with a history of ACS.
* **Myocardial Infarction (MI) with ST-segment elevation (STEMI):** In patients treated with fibrinolytic therapy, or primary PCI, ticagrelor is indicated to reduce the rate of thrombotic cardiovascular events.
## Adult Dosing
* **ACS:** 180 mg orally once as a single loading dose, followed by 90 mg orally twice daily for at least 12 months. After 12 months of treatment, consider continuing ticagrelor 90 mg twice daily for a total of up to 30 months in patients with a history of ACS.
* **STEMI:** 180 mg orally once as a single loading dose, followed by 90 mg orally twice daily. In patients treated with PCI, continue ticagrelor 90 mg twice daily for at least 12 months.
## Pediatric Dosing
Ticagrelor is not approved for use in pediatric patients. Safety and effectiveness have not been established.
## Dose Adjustments
No dose adjustments are recommended based on age, sex, race, or renal impairment. Dose adjustments for hepatic impairment are not specifically outlined, but caution is advised.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Major Bleeding:** The most significant risk. Can occur at any time and may be life-threatening.
* **Dyspnea:** Common, often transient, and usually not associated with underlying pulmonary disease.
* **Bradycardia:** Can occur, especially in patients taking other medications that cause bradycardia.
* **Ventricular Hemorrhage:** A rare but serious risk, particularly in patients treated with PCI.
* **Other:** Contusion, hypercholesterolemia, hypertension, cough.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure; strong inducers (e.g., rifampin, phenytoin) can decrease exposure.
* **CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4, increasing the exposure of sensitive substrates (e.g., simvastatin, atorvastatin).
* **Other Antiplatelet Agents and Anticoagulants:** Increased risk of bleeding. Concomitant use requires careful risk-benefit assessment.
* **Proton Pump Inhibitors (PPIs):** Some studies suggest PPIs may interfere with ticagrelor's efficacy, particularly omeprazole and esomeprazole. Avoid concurrent use if possible, or use with caution.
* **Medications that cause bradycardia:** Increased risk of symptomatic bradycardia.
## Monitoring
* **Bleeding:** Closely monitor for any signs or symptoms of bleeding (e.g., hematuria, melena, hematemesis, bruising).
* **Renal Function:** Monitor periodically.
* **Liver Function:** Monitor periodically.
* **Electrolytes:** Monitor periodically.
## Clinical Pearls
* Ticagrelor should be initiated as soon as possible in patients with ACS.
* If a dose of ticagrelor is missed, the patient should take the next dose at the regularly scheduled time. Do not double the dose.
* Discontinuation of ticagrelor before completing the recommended duration of therapy may lead to an increased risk of thrombotic events.
* Ticagrelor has a faster onset and offset of action compared to clopidogrel, which may be advantageous in certain situations.
* Patients experiencing dyspnea should have their condition evaluated. If other causes are ruled out, it is generally acceptable to continue ticagrelor.
***
**Educational Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information for ticagrelor and consider individual patient factors before making treatment decisions.
